The results of this study and others indicate that optimal care must prioritise an in-depth understanding of these pathways, with timely testing for all actionable biomarkers in a given tumour type, inclusive of RET fusion in NSCLC and TC and RET mutations in MTC, adapted and adaptable to the patient profile. The gene discussed is RET; the disease is non-small cell lung carcinoma.